Indication
Relapsing-Remitting Multiple Sclerosis
5 clinical trials
7 products
Clinical trial
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in EgyptStatus: Active (not recruiting), Estimated PCD: 2023-11-30
Product
FingolimodClinical trial
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light Levels (SOSTOS)Status: Recruiting, Estimated PCD: 2026-02-20
Product
OfatumumabProduct
Disease modifying treatmentClinical trial
A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple SclerosisStatus: Recruiting, Estimated PCD: 2025-07-07
Product
OcrelizumabProduct
TysabriProduct
Dimethyl FumarateClinical trial
Open-Label, Randomized, Multicenter, Multiple-Dose,Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label ExtensionStatus: Active (not recruiting), Estimated PCD: 2025-09-08
Product
Interferon β-1a